


**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (Currently amended) A compound of Formula I:



Formula I


Wherein:

~~R1~~ R<sub>1</sub> is unsubstituted or substituted pyridine; unsubstituted or substituted furyl; or unsubstituted or substituted thiophenyl; wherein the substitution may be one or more of the following: (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, (C1-C6)alkylthio, trifluoromethyl, halo, N-morpholino, or phenylthio;

~~R2~~ R<sub>2</sub> is unsubstituted or substituted quinoline; unsubstituted or substituted phenyl; unsubstituted or substituted naphthalene; unsubstituted or substituted pyridine; unsubstituted or substituted quinazoline; unsubstituted or substituted cinnoline; unsubstituted or substituted indole; unsubstituted or substituted imidazo[1,2-a]pyridin-2-yl; unsubstituted or substituted benzofuran; unsubstituted or substituted dihydrobenzofuran; unsubstituted or substituted dihydrobenzo[1,4]dioxane; unsubstituted or substituted benzodioxolane; unsubstituted or substituted benzothiophene; unsubstituted or substituted 2-aminobenzimidazole; unsubstituted or substituted imidazo[1,2-a]pyridine; wherein the substitution may independently be one or more of the following: hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6) alkylhalide, (C1-C6)alkoxy, (C2-C6)alkenyloxy, (C2-C6)alkynyloxy, (C1-C6)alkylthio, (C1-C6)alkylsulphinyl, (C1-C6)alkylsulphonyl, (C1-C6)alkylamino, di-[(C1-C6)alkyl]amino, (C1-C6)alkoxycarbonyl, N-(C1-C6)alkylcarbamoyl, N,N-di-[(C1-C6)alkyl]carbamoyl, aminooxy, N-(C1-C6)alkyl aminooxy, N,N-di-[(C1-C6)alkyl]aminooxy, (C2-C6)alkanoyl, (C2-C6)alkanoyloxy, (C2-C6)alkanoylamino, N-(C1-C6)alkyl-(C2-C6)alkanoylamino, (C3-C6)alkenoylamino, N-(C1-C6)alkyl-(C3-C6)alkenoylamino, (C3-C6)alkynoylamino, N-(C1-C6)alkyl-(C3-

C6)alkynoylamino, sulphamoyl, N-(C1-C6)alkylsulphamoyl, N,N-di-[(C1-C6)alkyl]sulphamoyl, (C1-C6)alkanesulphonylamino, N-(C1-C6)alkyl-(C1-C6)alkanesulphonylamino, carboxamide, ~~ethylene~~-phenyl, thiophenyl, aminophenyl, phenylthio, halo, cyano, pyridinyl, arylalkyl, hydroxy, N-pyrrolidino, N-morpholino, carboxyl, [5-phenyl-1,2,4-oxadiazole-3-yl]methoxy, 6-methyl-pyridazin-3-yl-oxy, (5-oxo-2-pyrrolidinyl)methoxy, 2-(4,5-dihydro-1H-imidazolyl), N, N-dialkylcarbamoyloxy, 1-hydroxy-1-methylethyl, 4-fluorophenyl, 3,4-methylenedioxyphenyl, trifluoromethyl, trifluoromethoxy,


or a group of the formula



wherein: X<sub>1</sub> is O, N, S, SO<sub>2</sub>, NR<sub>13</sub>, C(O), or bond; Q<sub>1</sub> is hydrogen, phenyl, 5-(2,2-difluoro-1,3-benzodioxolyl), C(O)Q<sub>5</sub>, or pyridyl when m and n are independently 0-2, except when one is 0 the other cannot be 0; Q<sub>1</sub> is OR<sub>11</sub>, NR<sub>11</sub>R<sub>12</sub>, halo, N-morpholino, N-piperazino-N'R<sub>13</sub>, N-imidazolyl, N-pyrazolyl, N-triazolyl, N-(4-piperidinylpiperidine), SO<sub>2</sub>R<sub>14</sub>, SOR<sub>14</sub>, NHSO<sub>2</sub>R<sub>15</sub>, acetamido, N-phthalimido, N-oxazolidino, N-imidazolino, N-benzoxazolidino, N-pyrrolidinonyl, N(N'-methylbenzimidazolino), N,N-di(C1-C4)alkylamino(C1-C4)alkoxy, N-benzimidazolino; ~~when m and n are independently 0-2, but one or the other of m or n is not 0~~; Q<sub>5</sub> is hydroxy, methoxy, amino, diethylamino, dimethylamino; R<sub>10</sub> is hydrogen, halo, (C1-C6)alkyl; R<sub>11</sub> and R<sub>12</sub> are independently hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, arylalkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkylmethyl, 4-(N-methylpiperidinyl), pyridyl, or R<sub>11</sub> and R<sub>10</sub> can be taken together to form a 4, 5, 6, or 7 membered ring, or R<sub>11</sub> and R<sub>12</sub> can be taken together to form a 3, 4, 5, 6, or 7 membered ring; R<sub>13</sub> is hydrogen, (C1-C6)alkyl, 2-methoxyphenyl, 2-pyridimidinyl; R<sub>14</sub> is 2-pyrimidinyl, N-methyl-2-imidazolyl, 4-chlorophenyl, 2-pyridylmethyl; R<sub>15</sub> is (C1-C6)alkyl, N-methyl-4-imidazolyl; R<sub>16</sub> is hydrogen, halo, arylalkyl, or aryl, ~~or a group of the formula~~


(C4)alkylamino(C1-C4)alkoxy, N-benzimidazolino; when m and n are independently 0-2, but one or the other of m or n is not 0; Q<sub>5</sub> is hydroxy, methoxy, amino, diethylamino, dimethylamino; R<sub>10</sub> is hydrogen, halo, (C1-C6)alkyl; R<sub>11</sub> and R<sub>12</sub> are independently hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, arylalkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkylmethyl, 4-(N-methylpiperidinyl), pyridyl, or R<sub>11</sub> and R<sub>10</sub> can be taken together to form a 4, 5, 6, or 7 membered ring, or R<sub>11</sub> and R<sub>12</sub> can be taken together to form a 3, 4, 5, 6, or 7 membered ring; R<sub>13</sub> is hydrogen, (C1-C6)alkyl, 2-methoxyphenyl, 2-pyridimidinyl; R<sub>14</sub> is 2-pyrimidinyl, N-methyl-2-imidazolyl, 4-chlorophenyl, 2-pyridylmethyl; R<sub>15</sub> is (C1-C6)alkyl, N-methyl-4-imidazolyl; R<sub>16</sub> is hydrogen, halo, arylalkyl, aryl,

or a group of the formula:



wherein: Q<sub>2</sub> is hydrogen, 4-imidazolyl, or C(O)NR<sub>24</sub>R<sub>25</sub> when o and p are independently 0-2; Q<sub>2</sub> is OR<sub>23</sub>, NR<sub>24</sub>R<sub>25</sub>, or N-morpholino, when o and p are independently 0-2, but one or the other of o or p is not 0; R<sub>20</sub> is hydrogen, or (C1-C6)alkyl; R<sub>21</sub> is hydrogen, (C1-C6)alkyl, or R<sub>21</sub> and R<sub>20</sub> can be taken together to form a 4, 5, 6, or 7 membered ring; R<sub>22</sub> is hydrogen, (C1-C6)alkyl, arylalkyl, aryl, or R<sub>21</sub> and R<sub>22</sub> can be taken together to be a 3, 4, 5, 6, 7 membered ring; R<sub>23</sub> is hydrogen or (C1-C6)alkyl; R<sub>24</sub> is hydrogen, (C1-C6)alkyl, or R<sub>24</sub> and R<sub>25</sub> can be taken together to form a 3, 4, 5, 6, or 7 membered ring, or R<sub>24</sub> and R<sub>20</sub> can be taken together to form a 6 or 7 membered ring; R<sub>25</sub> is hydrogen, (C1-C6)alkyl, or acetyl,

or a group of the formula




wherein:  $\text{R}_{30}$  is hydrogen, or (C1-C6)alkyl;  $\text{R}_{31}$  is hydrogen, (C1-C6)alkyl, 2-pyridyl, pyridylmethyl, amino, or hydroxy,

or a group of the formula




wherein:  $\text{R}_{32}$  and  $\text{R}_{33}$  are each independently hydrogen, (C1-C6)alkyl, acetyl, (C1-C4)alkylsulphonyl, or  $\text{R}_{32}$  and  $\text{R}_{33}$  can be taken together to form a 4, 5, 6, or 7 membered ring,

or a group of the formula




wherein:  $\text{X}_2$  is  $\text{CH}_2$ , O, or N;  ~~$q$  is 2-3 except when  $\text{Q}_3$  is a bond~~,  $q$  is 0-3;  $\text{Q}_3$  is  $\text{NR}_{36}\text{R}_{37}$ , or  $\text{OR}_{38}$ , and  $\text{R}_{35}$  is hydrogen, or  $\text{R}_{35}$  and  $\text{Q}_3$  can be taken together to form a 5 membered ring;  $\text{R}_{36}$ ,  $\text{R}_{37}$ , and  $\text{R}_{38}$  are each independently hydrogen, or (C1-C6)alkyl,

or a group of the formula




wherein:  $\text{X}_3$  is cyano, carboxamide, N,N-dimethylcarboxamide, N,N-dimethylthiocarboxamide, N,N-dimethylaminomethyl, 4-methylpiperazin-1-yl-methyl or carboxylate,

or a group of the formula



wherein: Q<sub>6</sub> is NR<sub>41</sub>R<sub>42</sub>; r is 2-3; R<sub>40</sub> is hydrogen, or (C1-C6)alkyl; R<sub>41</sub> and R<sub>42</sub> are hydrogen, (C1-C6)alkyl, or R<sub>41</sub> and R<sub>40</sub> can be taken together to form a 6 or 7 membered ring,

or a group of the formula




wherein: Q<sub>7</sub> is hydroxy, methoxy, dimethylamino, or N-piperidinyl;

and wherein R<sub>7</sub> is hydrogen; benzyl; aryl; ~~C<sub>1</sub>-C<sub>4</sub>alkyl~~ C<sub>1</sub>-C<sub>4</sub> alkyl; halogen; ~~CO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub>alkyl)~~ CO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub>alkyl); ~~CONR<sub>6</sub>R<sub>6</sub>~~ CONR<sub>6</sub>R<sub>6</sub>; ~~C<sub>1</sub>-C<sub>4</sub>alcohol~~ C<sub>1</sub>-C<sub>4</sub> alcohol; ~~SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub>alkyl)~~ SO<sub>2</sub>(C<sub>1</sub>-C<sub>4</sub>alkyl); ~~COR<sub>8</sub>~~ COR<sub>8</sub>; wherein R<sub>6</sub> is ~~(C<sub>1</sub>-C<sub>4</sub>alkyl)~~ (C<sub>1</sub>-C<sub>4</sub>alkyl) R<sub>9</sub>; R<sub>8</sub> is ~~(C<sub>1</sub>-C<sub>4</sub>alkyl)~~ (C<sub>1</sub>-C<sub>4</sub>alkyl) or ~~(C<sub>2</sub>-C<sub>4</sub>alkenyl)~~ (C<sub>2</sub>-C<sub>4</sub> alkenyl); and R<sub>9</sub> is NR<sub>3</sub>R<sub>4</sub>, wherein R<sub>3</sub> and R<sub>4</sub> are each independently ~~(C<sub>1</sub>-C<sub>4</sub>alkyl)~~ (C<sub>1</sub>-C<sub>4</sub>alkyl);


and the pharmaceutically acceptable salts, esters and prodrugs thereof.

2. (Currently amended) A compound according to Claim 1 of the formula:



where R<sub>2</sub> is substituted or unsubstituted 4-quinoline.

3. (Currently amended) A compound according to Claim 1 of the formula:



where R<sub>2</sub> is substituted or unsubstituted phenyl.

4. (Currently amended) A compound of ~~either of Claims 1, 2, or 3~~ of Claim 1 where R<sub>1</sub> is substituted or unsubstituted 2-pyridyl.

5. (Currently amended) A compound of ~~either of Claims 1, 2, or 3~~ of Claim 1 where R<sub>7</sub> is hydrogen.

6. (Original) A compound according to Claim 1 selected from the group comprising:

4-[2-(6-Ethyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline,  
[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid methyl ester,  
4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-6-carboxylic acid methyl ester,  
4-(5-Benzyl-2-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid methyl ester,  
3-(4-Fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine-6-carboxylic acid (2-dimethylamino-ethyl)-amide,  
4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-6-carboxylic acid (2-dimethylamino-ethyl)-amide,  
4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid (2-dimethylamino-ethyl)-amide,  
5-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-benzofuran-2-carboxylic acid (2-dimethyl amino-ethyl)-amide,  
4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide,  
4-[2-(6-Methoxy-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline,

4-[2-(6-Ethoxy-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline,  
3-(4-Fluoro-phenyl)-2-(6-methoxy-pyridin-2-yl)-pyrazolo[1,5-a]pyridine,  
2-(6-Ethoxy-pyridin-2-yl)-3-(4-fluoro-phenyl)-pyrazolo[1,5-a]pyridine,  
7-Benzyl-4-[2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline,  
3-{4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yl}-acrylic acid methyl ester,  
3-{4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yl}-acrylic acid,  
4-[2-(6-Ethylsulfanyl-pyridin-2-yl)-pyrazolo[1,5-a]-pyridin-3-yl]-quinoline,  
4-[2-(6-Phenylsulfanyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline,  
4-[2-(6-Morpholin-4-yl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline,  
3-(4-Fluoro-phenyl)-2-(6-methylsulfanyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine,  
3-(4-Methylsulfanyl-phenyl)-2-(6-methylsulfanyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine,  
Dimethyl-(2-{4-[2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-ylsulfanyl}-ethyl)-amine,  
2-(Pyridin-2-yl)-3-(quinolin-4-yl)-pyrazolo[1,5-a]pyridine-5-carboxylic acid dimethylamide,  
2-(Pyridin-2-yl)-3-(quinolin-4-yl)-pyrazolo[1,5-a]pyridine-6-carboxylic acid dimethylamide,  
4-[2-(6-Vinyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline,  
6-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-imidazo[1,2-a]pyridin-2-yl-amine,  
6-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-1H-benzoimidazol-2-yl-amine,

[3-(4-Fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-6-yl]-methanol,

6-Allyloxymethyl-3-(4-fluoro-phenyl)-2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine,

4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide,

3-{4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yl}-propionamide,

3-{4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yl}-N-(3-pyrrolidin-1-yl-propyl)-propionamide,

N-(2-Dimethylamino-ethyl)-3-{4-[2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yl}-propionamide,

2-Pyridin-2-yl-3-quinolin-4-yl-pyrazolo[1,5-a]pyridine-5-carboxylic acid (3-dimethylamino-propyl)-amide,

4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid (2-hydroxy-ethyl)-amide,

4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid hydrazide,

4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid (3-hydroxy-propyl)-amide,

4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid methylamide,

4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid (3-ethoxy-propyl)-amide,

4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid (3-morpholin-4-yl-propyl)-amide,

4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid (3-dimethylamino-propyl)-amide,

4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid [2-(2-methoxy-phenyl)-ethyl]-amide,



4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinoline-7-carboxylic acid amide,  
Dimethyl-(3-{4-[2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yloxy}-propyl)-amine,  
4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-7-(2-morpholin-4-yl-ethoxy)-quinoline,  
Diisopropyl-(2-{4-[2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yloxy}-ethyl)-amine,  
4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-7-(2-pyrrol-1-yl-ethoxy)-quinoline,  
Dimethyl-(1-methyl-2-{4-[2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yloxy}ethyl)-amine,  
Methyl-(3-{4-[2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yl-oxy}-propyl)-amine,  
4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-7-(2-piperidin-1-yl-ethoxy)-quinoline,  
Diethyl-(2-{4-[2-(6-methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yloxy}-ethyl)-amine,  
Dimethyl-{3-[4-(2-pyridin-2-yl-pyrazolo[1,5-a]pyridin-3-yl)-quinolin-7-yloxy]-propyl}-amine,  
7-(2-Morpholin-4-yl-ethoxy)-4-(2-pyridin-2-yl-pyrazolo[1,5-a]pyridin-3-yl)-quinoline,  
Diisopropyl-{2-[4-(2-pyridin-2-yl-pyrazolo[1,5-a]pyridin-3-yl)-quinolin-7-yloxy]-ethyl}-amine,  
4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-7-(3-morpholin-4-yl-propoxy)-quinoline,  
1-(3-{4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridine-3-yl]-quinolin-7-yloxy}-propyl)-1,3-dihydro-benzoimidazol-2-one  
3-{4-[2-(6-Methyl-pyridin-2-yl)-pyrazolo[1,5-a]pyridin-3-yl]-quinolin-7-yl}-propionic acid methyl ester,  
Diethyl-{3-[4-(2-pyridin-2-yl-pyrazolo[1,5-a]pyridin-3-yl)-quinolin-7-yloxy]-propyl}-amine,

Ethyl-methyl-{3-[4-(2-pyridin-2-yl-pyrazolo[1,5-a]pyridin-3-yl)-quinolin-7-yloxy]-propyl}-amine,

4-(2-Pyridin-2-yl-pyrazolo[1,5-a]pyridin-3-yl)-7-(3-pyrrolidin-1-yl-propoxy)-quinoline,

7-(3-Piperidin-1-yl-propoxy)-4-(2-pyridin-2-yl-pyrazolo[1,5-a]pyridin-3-yl)-quinoline,

Diethyl-{2-[4-(2-pyridin-2-yl-pyrazolo[1,5-a]pyridin-3-yl)-quinolin-7-yloxy]-ethyl}-amine,

Dimethyl-{2-[4-(2-pyridin-2-yl-pyrazolo[1,5-a]pyridin-3-yl)-quinolin-7-yloxy]-ethyl}-amine,

and the pharmaceutically acceptable salts, esters and prodrugs thereof.

7. (Currently amended) A pharmaceutical formulation comprising a compound according to ~~any one of Claims 1 to 6 or the pharmaceutically acceptable salt, ester or prodrug thereof~~ Claim 1 in admixture with an acceptable pharmaceutical carrier or excipient.

8. (Currently amended) A method of inhibiting TGF-beta Type I Receptor Kinase in a mammal comprising administering to a mammal in need of such treatment an TGF-beta Type I receptor kinase inhibiting amount of a compound according to compound according to ~~any one of Claims 1 to 6, or the pharmaceutical formulation of claim 7~~ Claim 1.

9. (Currently amended) A method of treating conditions resulting from excessive production of TGF-beta in a mammal in need of such treatment comprising administering a TGF-beta-suppressing amount of a compound according to ~~any one of Claims 1 to 6, or the pharmaceutical formulation of claim 7~~ Claim 1.

10. (Currently amended) A method of treating cancer in a mammal in need thereof comprising administering to said patient a therapeutically effective amount a compound according to ~~any one of Claims 1 to 6, or the pharmaceutical formulation of claim 7~~ Claim 1.

11. (Canceled).

X-15495  
Preliminary Amendment

12. (Canceled).

13. (Canceled).